title: Intracoronary Reopro during Percutaneous Coronary Intervention in Acute and Stable Patient can Influence Stent Thrombosis Formation (IRPASST) Study.
abstract: BACKGROUND
  In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration. Intracoronary (IC) bolus application of abciximab causes very high local drug concentrations and may be more effective in reducing acute and sub-acute stent thrombosis (ST). We studied whether IC bolus administration of abciximab is associated with a reduced ST and target vessels revascularization (TVR); therefore, less MACE rate compared with the standard intravenous IV bolus and infusion application.
  
  
  METHODS
  This was a single-center observational study conducted between June 2007 and 2009. We studied a total of 447 patients admitted with either acute coronary intervention (PCI) and stenting. Patients with bleeding disorder, recent major surgery and high blood pressure were excluded. Patients were divided into two groups: Group I (n = 199) patient received IC bolus of abciximab (reopro) 0.25 μg/kg during the PCI in cath lab. Group II (n = 248) received the standard dose of reopro-a bolus intravenous 0.25 μg/kg and maintenance dose of 0.125 μg/kg over 12 h.
  
  
  RESULTS
  There were no differences between the groups with regard to diabetes mellitus, group I (56%) vs. group II (58%), P = 0.613; ACS, group I (38%) vs. group II (44%), P = 0.175; Dietthylstilbestrol Drug eluted stent (DES) in group I (66.5%) vs. (57.6%) group II, P = 0.056; Bare Metal Stent (BMS) in group I (33%) vs. (40.7%) group II, P=0.093; target vessel revascularization (TRV) was seen in 9 patients (4%) in group I vs. 16 patients (6%) in group II. ST elevation was seen in 4 patients (2%) in group I vs. 7 patients (2.8%) in group II, all presented with STEMI.
  
  
  CONCLUSIONS
  In this study, there was a trend toward less ST and TVR in patients who received IC reopro vs. intravenous route both in ACS and stable CAD. The percentage of DM was high in both groups (56%), especially in Saudi patients. In-stent restenosis (ISR) was less in group I than in group II, this was mainly associated with BMS usage. The percentage of BMS was more than 30% in both groups, either due to STEMI cases or large vessel size. Randomized controlled trials are warranted to further assess IC application of abciximab in reducing ST.
authors: King Saud Bin Abdulaziz University for Health Sciences, KACC, National Guard, Riyadh, Kingdom of Saudi Arabia.
authors: Mohammed
authors: M
authors: Balghith
authors: Ali
authors: A
authors: Al-Ghamdi
authors: El Harif
authors: el H
authors: Zain
authors: Ahmed
authors: A
authors: Al-Saileek
keywords: Abciximab; acute coronary artery disease; intracoronary; intravenous; stent thrombosis; tirofiban
references: Thromb Haemost. 2002 Jun;87(6):1020-5
references: 12083481
references: Int J Clin Pract. 1999 Dec;53(8):604-7
references: 10692754
references: Eur Heart J. 2008 Feb;29(4):455-61
references: 18158289
references: Circulation. 1998 Dec 15;98(24):2695-701
references: 9851955
references: N Engl J Med. 1999 May 27;340(21):1623-9
references: 10341274
references: Am Heart J. 2000 May;139(5):824-9
references: 10783216
references: J Am Coll Cardiol. 2001 Dec;38(7):2114-30
references: 11738323
references: J Thromb Thrombolysis. 2007 Feb;23(1):57-63
references: 17160551
references: Circulation. 2008 Jul 1;118(1):49-57
references: 18559698
references: Circulation. 2004 Aug 3;110(5):588-636
references: 15289388
references: Am Heart J. 2005 Nov;150(5):1015
references: 16290988
references: Rev Esp Cardiol. 2006 Jun;59(6):567-74
references: 16790200
references: Eur Heart J. 1999 Nov;20(21):1572-8
references: 10529325
references: Catheter Cardiovasc Interv. 2004 Jun;62(2):186-92
references: 15170708
references: J Interv Cardiol. 2010 Dec;23(6):554-9
references: 20624200
references: JAMA. 2005 Apr 13;293(14):1759-65
references: 15827315
references: Am J Cardiol. 2004 Oct 15;94(8):983-8
references: 15476608
references: Circulation. 1998 May 5;97(17):1680-8
references: 9591761
references: Can J Cardiol. 2009 Jul;25(7):e255-8
references: 19584982
references: N Engl J Med. 2008 May 22;358(21):2205-17
references: 18499565
references: J Am Coll Cardiol. 2007 Apr 10;49(14):1517-24
references: 17418289
references: Circulation. 1999 Aug 24;100(8):799-806
references: 10458714